Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zippelius

Showing results (291-300 of 308) with videos related to

Pageof 31
Sort By:
Communications Medicine|July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancerChristoph Schultheiß, Brenda Besemer, Edith Willscher, et al.
Science Immunology|May 10, 2024
Nucleobase adducts bind MR1 and stimulate MR1-restricted T cellsAlessandro Vacchini, Andrew Chancellor, Qinmei Yang, et al.
Immunity|June 14, 2023
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responsesFelix Bayerl, Philippa Meiser, Sainitin Donakonda, et al.
Spine|April 12, 2024
Association Between Severity of Cervical Central Spinal Stenosis and Paraspinal Muscle Parameters in Patients Undergoing Anterior Cervical Discectomy and FusionThomas Caffard, Artine Arzani, Bruno Verna, et al.
Oncotarget|October 21, 2017
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibitionGongda Xue, Reto Kohler, Fengyuan Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II TrialSacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
Science Translational Medicine|November 2, 2022
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockadeMichal A Stanczak, Natalia Rodrigues Mantuano, Nicole Kirchhammer, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancerAlexandros Papachristofilou, Madeleine M Hipp, Ute Klinkhardt, et al.
Nature Communications|February 2, 2023
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapyMarcel P Trefny, Nicole Kirchhammer, Priska Auf der Maur, et al.
Pageof 31

Showing results (291-300 of 308) with videos related to

Sort By:
Pageof 31
Communications Medicine|July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancerChristoph Schultheiß, Brenda Besemer, Edith Willscher, et al.
Science Immunology|May 10, 2024
Nucleobase adducts bind MR1 and stimulate MR1-restricted T cellsAlessandro Vacchini, Andrew Chancellor, Qinmei Yang, et al.
Immunity|June 14, 2023
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responsesFelix Bayerl, Philippa Meiser, Sainitin Donakonda, et al.
Spine|April 12, 2024
Association Between Severity of Cervical Central Spinal Stenosis and Paraspinal Muscle Parameters in Patients Undergoing Anterior Cervical Discectomy and FusionThomas Caffard, Artine Arzani, Bruno Verna, et al.
Oncotarget|October 21, 2017
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibitionGongda Xue, Reto Kohler, Fengyuan Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II TrialSacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
Science Translational Medicine|November 2, 2022
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockadeMichal A Stanczak, Natalia Rodrigues Mantuano, Nicole Kirchhammer, et al.
Journal for Immunotherapy of Cancer|February 10, 2019
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancerAlexandros Papachristofilou, Madeleine M Hipp, Ute Klinkhardt, et al.
Nature Communications|February 2, 2023
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapyMarcel P Trefny, Nicole Kirchhammer, Priska Auf der Maur, et al.
Pageof 31